• Explore /
  • Poster
  • / First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.

First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.

Abstract Poster

Authors

Stephane Oudard

Stephane Oudard

Georges Pompidou European Hospital, Paris, France

Stephane Oudard , Lisa Sengelov , Paul N. Mainwaring , Antoine Thiery- Vuillemin , Christine Theodore , Evgeny Kulikov , Jeffrey Yachnin , Ivo Kocak , Vesa V Kataja , Marjaana Luukkaa , Aleander Nosov , Marie Hjelm-Eriksson , Jeffrey Bubis , Liji Shen , Marie-Laure Risse , A. Oliver Sartor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01308567

Citation

J Clin Oncol 30, 2012 (suppl; abstr TPS4696^)

Abstract #

TPS4696^

Poster Bd #

16G

Abstract Disclosures

Similar Posters

First Author: Mario A. Eisenberger

First Author: Simon J. Crabb

First Author: Ethan M. Basch

First Author: Susan Halabi